Talk:Lumateperone

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Lumateperone.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

External links modified

Hello fellow Wikipedians,

I have just modified 3 external links on Lumateperone. Please take a moment to review my edit. If you have any questions, or need the bot to ignore the links, or the page altogether, please visit this simple FaQ for additional information. I made the following changes:

When you have finished reviewing my changes, you may follow the instructions on the template below to fix any issues with the URLs.

This message was posted before February 2018. After February 2018, "External links modified" talk page sections are no longer generated or monitored by InternetArchiveBot. No special action is required regarding these talk page notices, other than regular verification using the archive tool instructions below. Editors have permission to delete these "External links modified" talk page sections if they want to de-clutter talk pages, but see the RfC before doing mass systematic removals. This message is updated dynamically through the template {{source check}} (last update: 5 June 2024).

If you have discovered URLs which were erroneously considered dead by the bot, you can report them with this tool.
If you found an error with any archives or the URLs themselves, you can fix them with this tool.

Cheers.—InternetArchiveBot (Report bug) 01:33, 9 January 2018 (UTC)[reply]

Advertising

This article is in dire need of a makeover. Most of the sources are not independent: either they are straight from the horse's mouth (also called a "press release") or written by authors serving in the employment of the sponsoring pharmaceutical company. ―Biochemistry🙴❤ 22:38, 9 July 2019 (UTC)[reply]

I think we need to delete everything except the lede (which cites an excerpt from a reference work on small-molecule drugs for schizophrenia with no apparent link to the drug's clinical trial sponsors as its sole source). Everything else depends on primary sources, which are not in this case allowable sources for facts stated in wikipedia according to WP:PRIMARY.

WP:PROMO applies in the cases where the clinical efficacy and incidence of adverse drug effects compared to other drugs are mentioned. Finally, the article copy makes each statement in wikivoice, but the authors of every paper cited are affiliated with the clinical trial sponsors, so those sources fail the requirement that the sources be independent, third-party sources. Those statements must go, because by WP:MEDRS guideline, they're not adequately sourced.

Ordinarily, I'd wait for a consensus before acting, but that could take a month or more. In that time readers would be exposed to medical information in wikivoice that violates our WP:NPOV ethic. Those parts of the article should be removed now under WP:BOLD. I'll take care of that.

Anyone associated with the clinical trial sponsors for the drug which is the subject of this article should, in the order stated:

declare your affiliations with the company developing this drug and/or clinical trial sponsor (see WP:COI),
read WP:RS,WP:PRIMARY, WP:PROMO, WP:MEDRS, and especially WP:NPOV,
seek consensus on this talk page before reverting any change or restoring any material relative to the subject of this artlcle.

Thank you.--loupgarous (talk) 04:26, 5 October 2019 (UTC)[reply]

Numbers

Regarding this diff (by Boghog) and that diff, that diff number two (both by 75.165.16.84). Does the 10.1358/dot.2018.54.12.2899443 journal (cited [14]) have a confirmation for the "4.1nM D1" and "3.2nM D2" and "serotonin transporters at 3.3nM." figures? The reason why I am asking this is because the official leaflet (www.caplyta.com --> "Prescribing Information" --> Page 4, Section 12.1 and the first paragraph of Section 12.2) has numbers which are an order of magnitude greater than those included in the article. Just editing the article without asking doesn't seem a great option, as source [14] is not downloadable. --Gryllida (talk) 21:23, 17 April 2020 (UTC)[reply]

Thanks for your question. Unfortunately I do not have access to the original source either. My contribution was based on the abstract only and I cannot verify or refute the values that were added later. In addition, it is not clear what kind of values these are nor the experimental conditions under which they were measured. Finally it is debatable whether this level of detail is appropriate for an encyclopedic article. Hence I have removed them. Boghog (talk) 05:43, 19 April 2020 (UTC)[reply]

Thanks for confirming and for the change.

I am wondering if there is a way to keep these figures -- for the sake of informing the reader -- without causing them to erroneously believe something that is wrong. Currently I see two options:

1) Would this be a better source for this?

Meyer, Jonathan M. "Lumateperone for schizophrenia." Current Psychiatry 19.2 (2020): 33-39.
- PDF from Google docs: link

Couldn't figure out how reliable of a source it is: single author, but perhaps peer reviewed? Doesn't say where these figures are from, either. Does it have to be some sort of a standard procedure before a new drug is allowed on the market?

2) Would writing with attribution, i.e. "According to the prescribing information leaflet, ... " or "According to the prescribing information leaflet, which didn't include a description of the research method, ... " be adequate?

Please let me know whether you would consider either of these two options acceptable, or leave it out entirely as poorly sourced.

Thanks, Gryllida (talk) 21:49, 19 April 2020 (UTC)[reply]

PMID 30596390 would have been the best source since it is indexed as a review in PubMed, but unfortunately I cannot access the full text document. Myer (2020) published in Current Psychiatry. This journal is not currently indexed in PubMed which makes this a questionable source. Myer in turn cites PMID 27042868 is a better source. This source reports the following values:

Receptor affinities^[1]
Receptor	K_i (nM)
5-HT_2A	0	.54
Dopamine receptor D₁	52
Dopamine receptor D₂	32

References

^ Davis RE, Correll CU (June 2016). "ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes". Expert Review of Neurotherapeutics. 16 (6): 601–14. doi:10.1080/14737175.2016.1174577. PMID 27042868.

Boghog (talk) 05:05, 20 April 2020 (UTC)[reply]

This looks good. Thank you for adding this to the article as a right aligned table, appreciated. Gryllida (talk) 00:45, 27 April 2020 (UTC)[reply]

Success rate with Lumateperone

What success rate this medication has in reducing auditory hallucinations? 120.18.13.125 (talk) 20:21, 13 October 2022 (UTC)[reply]

Side Effects

There is no mention of Akathisia or Tardive Dyskinesia which showed up in trials according to Drugs.com and other sources. Is it even mentioned that there is a black box warning as well? Lady Meg (talk) 23:44, 24 September 2024 (UTC)[reply]

Feel free to add to the page if you feel it is missing content! IntentionallyDense (talk) 14:18, 25 September 2024 (UTC)[reply]

[pmid27042868-1] Davis RE, Correll CU (June 2016). "ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes". Expert Review of Neurotherapeutics. 16 (6): 601–14. doi:10.1080/14737175.2016.1174577. PMID 27042868.

[1]